Abstract: Obesity is characterized by chronic low-grade inflammation, which is driven by macrophage infiltration in adipose tissue and leads to elevated cytokines such as interleukin-1β (IL-1β) in the circulation and tissues. Previous studies demonstrate that SENP3, a redox-sensitive SUMO2/3-specific protease, is strongly implicated in the development and progression of cancer and cardiovascular diseases. However, the role of SENP3 in obesity-associated inflammation remains largely unknown. To better understand the effects of SENP3 on adipose tissue macrophage (ATM) activation and function within the context of obesity, we generated mice with myeloid-specific deletion of SENP3 (Senp3<sup>flox/flox</sup>;Lyz2-Cre mice). We found that the expression of SENP3 is dramatically increased in ATMs during high-fat diet (HFD)-induced obesity in mice. Senp3<sup>flox/flox</sup>;Lyz2-Cre mice show lower body weight gain and reduced adiposity and adipocyte size after challenged with HFD and during aging. Myeloid-specific SENP3 deletion attenuates macrophage infiltration in adipose tissue and reduces serum levels of inflammatory factors during diet and age-induced obesity. Furthermore, we found that SENP3 knockout markedly inhibits cytokine release from macrophage after lipopolysaccharide and palmitic acid treatment in vitro. Mechanistically, in cultured peritoneal macrophages, SENP3 protein level is enhanced by IL-1β, in parallel with the upregulation of Yes-associated protein 1 (YAP1). Moreover, we demonstrated that SENP3 modulates de-SUMO modification of YAP1 and SENP3 deletion abolishes the upregulation of YAP1 induced by IL-1β. Most importantly, SENP3 deficiency reduces YAP1 protein level in adipose tissue during obesity. Our results highlight the important role of SENP3 in ATM inflammation and diet and age-induced obesity.
Introduction
Obesity is more than just an accumulation of fat; it is a state of chronic, low-grade inflammation. This inflammation is largely driven by adipose tissue macrophages (ATMs)—immune cells that infiltrate fat tissue and secrete inflammatory cytokines like Interleukin-1β (IL-1β). These cytokines create a cycle that worsens metabolic health. While macrophages are known drivers of this process, the precise molecular switches that activate them in obese tissue are not fully understood. This study focuses on SENP3, a protease that regulates protein function through de-SUMOylation, and its role in obesity-associated inflammation.
Methods
The researchers employed a mix of in vivo mouse models and in vitro cell signaling assays:
- Conditional Knockout Mice: They generated a myeloid-specific SENP3-deficient mouse line ($Senp3^{flox/flox}; Lyz2-Cre$) to study the effect of losing SENP3 specifically in macrophages.
- Obesity Challenges: Mice were subjected to diet-induced obesity (a 60% kcal high-fat diet for 24 weeks) and age-induced obesity (monitoring up to 18 months).
- Molecular Analysis: Techniques like qPCR, Western blotting, and Immunoprecipitation (IP) were used to measure gene expression and protein modifications (SUMOylation).
- Histology: Adipose tissue was examined for "crown-like structures" (CLSs)—clusters of macrophages surrounding dead fat cells.
Key Results
SENP3 as an Obesity Sensor
The study first established that SENP3 expression in fat tissue macrophages spikes dramatically during weight gain. In response to high-fat diet (HFD) and inflammatory signals like LPS, SENP3 levels increase, suggesting it acts as a molecular sensor for metabolic stress.
Protection Against Obesity and Inflammation
Myeloid-SENP3 knockout mice gained significantly less weight on a high-fat diet compared to wild-type littermates. These mice had smaller fat cells (adipocytes), fewer inflammatory crown-like structures, and significantly lower serum levels of major inflammatory markers like IL-1β, IL-6, and TNFα.
The YAP1 Stability Mechanism
The researchers identified YAP1 as a critical player in this inflammatory pathway. SENP3 de-SUMOylates YAP1, which prevents its degradation and stabilizes the protein. When SENP3 is missing, YAP1 levels drop, leading to decreased activation of the NF-κB pathway. This effectively silences the inflammatory response and prevents the metabolic decline typically associated with obesity.
Discussion and Limitations
This study highlights SENP3 as a potential therapeutic target for metabolic syndrome. By breaking the link between macrophage activation and fat accumulation, SENP3 deficiency provides systemic protection. However, some limitations remain. Detecting the specific SUMOylated version of YAP1 in primary cells is challenging due to low abundance, requiring the use of overexpressed proteins in cell lines for biochemical proof. Additionally, while the YAP1 link is strong, SENP3 likely has other substrates in macrophages that may contribute to the observed anti-obesity effects. Future work will determine if SENP3 inhibitors can be translated into human treatments for obesity and "inflammaging."
Summary updated